WallStSmart

Boston Scientific Corp (BSX)vsTurning Point Brands Inc (TPB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 4235% more annual revenue ($20.07B vs $463.06M). BSX leads profitability with a 14.4% profit margin vs 12.6%. TPB appears more attractively valued with a PEG of 0.05. TPB earns a higher WallStSmart Score of 73/100 (B).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

TPB

Strong Buy

73

out of 100

Grade: B

Growth: 8.7Profit: 7.5Value: 8.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued
TPBUndervalued (+12.1%)

Margin of Safety

+12.1%

Fair Value

$145.55

Current Price

$88.39

$57.16 discount

UndervaluedFair: $145.55Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

TPB4 strengths · Avg: 9.3/10
PEG RatioValuation
0.0510/10

Growing faster than its price suggests

EPS GrowthGrowth
194.5%10/10

Earnings expanding 194.5% YoY

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

Revenue GrowthGrowth
29.2%8/10

Revenue surging 29.2% year-over-year

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

TPB2 concerns · Avg: 3.5/10
P/E RatioValuation
28.4x4/10

Moderate valuation

Market CapQuality
$1.69B3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : TPB

The strongest argument for TPB centers on PEG Ratio, EPS Growth, Return on Equity. Revenue growth of 29.2% demonstrates continued momentum. PEG of 0.05 suggests the stock is reasonably priced for its growth.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : TPB

The primary concerns for TPB are P/E Ratio, Market Cap.

Key Dynamics to Monitor

TPB carries more volatility with a beta of 0.85 — expect wider price swings.

TPB is growing revenue faster at 29.2% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TPB scores higher overall (73/100 vs 63/100) and 29.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Turning Point Brands Inc

CONSUMER DEFENSIVE · TOBACCO · USA

Turning Point Brands, Inc. manufactures, markets and distributes branded consumer products. The company is headquartered in Louisville, Kentucky.

Want to dig deeper into these stocks?